IL316574A - Structures of antibodies against ROR - Google Patents

Structures of antibodies against ROR

Info

Publication number
IL316574A
IL316574A IL316574A IL31657424A IL316574A IL 316574 A IL316574 A IL 316574A IL 316574 A IL316574 A IL 316574A IL 31657424 A IL31657424 A IL 31657424A IL 316574 A IL316574 A IL 316574A
Authority
IL
Israel
Prior art keywords
seq
heavy chain
light chain
domain
cdr2
Prior art date
Application number
IL316574A
Other languages
English (en)
Hebrew (he)
Inventor
Bailey Lucas
Agnieszka Nocula-Lugowska Malgorzata
Li Qufei
GLASER Bryan
Original Assignee
Exelixis Inc
Bailey Lucas
Malgorzata Agnieszka Nocula Lugowska
Li Qufei
GLASER Bryan
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Exelixis Inc, Bailey Lucas, Malgorzata Agnieszka Nocula Lugowska, Li Qufei, GLASER Bryan filed Critical Exelixis Inc
Publication of IL316574A publication Critical patent/IL316574A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/35—Valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/522—CH1 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
IL316574A 2018-04-18 2019-04-18 Structures of antibodies against ROR IL316574A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862659635P 2018-04-18 2018-04-18
PCT/US2019/028051 WO2019204564A1 (en) 2018-04-18 2019-04-18 Anti-ror antibody constructs

Publications (1)

Publication Number Publication Date
IL316574A true IL316574A (en) 2024-12-01

Family

ID=68239890

Family Applications (2)

Application Number Title Priority Date Filing Date
IL316574A IL316574A (en) 2018-04-18 2019-04-18 Structures of antibodies against ROR
IL278061A IL278061A (en) 2018-04-18 2020-10-14 Structures of antibodies against ROR

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL278061A IL278061A (en) 2018-04-18 2020-10-14 Structures of antibodies against ROR

Country Status (15)

Country Link
US (2) US12084496B2 (enExample)
EP (1) EP3797122A4 (enExample)
JP (3) JP2021522162A (enExample)
KR (1) KR20200143470A (enExample)
CN (1) CN112384533A (enExample)
AU (2) AU2019256431B2 (enExample)
BR (1) BR112020021269A2 (enExample)
CA (1) CA3097704A1 (enExample)
EA (1) EA202092202A1 (enExample)
IL (2) IL316574A (enExample)
MX (4) MX2020010881A (enExample)
MY (1) MY207121A (enExample)
PH (1) PH12020551716A1 (enExample)
SG (1) SG11202010235QA (enExample)
WO (1) WO2019204564A1 (enExample)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL326918A (en) * 2016-10-19 2026-05-01 Invenra Inc Antibody structures
CN113480656B (zh) * 2020-08-24 2022-06-03 岸迈生物科技(苏州)有限公司 抗ror1抗体
CA3172530A1 (en) 2021-02-25 2022-09-01 Spencer PARK Ror1 targeting chimeric antigen receptor
WO2023019121A2 (en) * 2021-08-09 2023-02-16 Merck Patent Gmbh Proteins that decouple t cell-mediated tumor cytotoxicity from release of pro-inflammatory cytokines
WO2023077026A1 (en) 2021-10-28 2023-05-04 Lyell Immunopharma, Inc. Methods for culturing cells expressing ror1-binding protein
TW202346330A (zh) * 2022-03-18 2023-12-01 美商長典生物晶片股份有限公司 抗豬繁殖與呼吸道綜合症病毒的抗體及其用途
TW202408589A (zh) 2022-06-30 2024-03-01 美商舒卓生物製藥公司 抗ror1抗體及抗體結合物、包含抗ror1抗體或抗體結合物之組合物，及製造及使用抗ror1抗體及抗體結合物之方法
WO2024207177A1 (en) * 2023-04-04 2024-10-10 Genequantum Healthcare (Suzhou) Co., Ltd. Antibody, linkers, payload, conjugates and applications thereof
AU2023313641A1 (en) * 2022-07-26 2025-03-13 Aimed Bio Inc. Anti-ror1 antibody and use thereof
WO2024064952A1 (en) 2022-09-23 2024-03-28 Lyell Immunopharma, Inc. Methods for culturing nr4a-deficient cells overexpressing c-jun
WO2024064958A1 (en) 2022-09-23 2024-03-28 Lyell Immunopharma, Inc. Methods for culturing nr4a-deficient cells
WO2024077174A1 (en) 2022-10-05 2024-04-11 Lyell Immunopharma, Inc. Methods for culturing nr4a-deficient cells
GB202216284D0 (en) * 2022-11-02 2022-12-14 Ucl Business Ltd Self-regulation
EP4638506A1 (en) * 2022-12-20 2025-10-29 Oncternal Therapeutics, Inc. Combination therapies for the treatment of cancer
KR20260056331A (ko) * 2023-07-20 2026-04-24 엑셀리시스, 인코포레이티드 활성화 가능한 티로신-단백질 키나제 막 수용체(ror) 항체-약물 접합체 및 이의 용도
CN121752598A (zh) * 2023-07-20 2026-03-27 埃克塞里艾克西斯公司 酪氨酸蛋白激酶膜受体1 (ror1)抗体-药物缀合物和其用途
CN121843961A (zh) * 2023-07-20 2026-04-10 埃克塞里艾克西斯公司 可活化的ror结合剂和其用途
WO2025132812A1 (en) * 2023-12-20 2025-06-26 Antalgenics, S.L. Phospholipase c inhibitor peptides and uses thereof
WO2025217398A1 (en) 2024-04-10 2025-10-16 Lyell Immunopharma, Inc. Methods for culturing cells with improved culture medium

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100508289B1 (ko) 1998-04-21 2005-08-17 마이크로메트 에이지 Ｃｄ１９×ｃｄ３ 특이 폴리펩티드 및 그의 용도
US7985783B2 (en) 2006-09-21 2011-07-26 The Regents Of The University Of California Aldehyde tags, uses thereof in site-specific protein modification
AU2010238723A1 (en) * 2009-04-23 2011-11-10 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Anti-human ROR1 antibodies
WO2011079902A2 (en) * 2009-12-18 2011-07-07 Biolnvent International Ab Biological materials and uses thereof
WO2011159847A2 (en) * 2010-06-15 2011-12-22 The Regents Of The University Of California Receptor tyrosine kinase-like orphan receptor 1 (ror1) single chain fv antibody fragment conjugates and methods of use thereof
EP3219731A1 (en) 2010-10-01 2017-09-20 Oxford BioTherapeutics Ltd Anti-ror1 antibodies
CA2818992C (en) 2010-12-01 2021-05-04 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Chimeric rabbit/human ror1 antibodies
CA2881966C (en) * 2012-08-24 2020-10-06 The Regents Of The University Of California Antibodies and vaccines for use in treating ror1 cancers and inhibiting metastasis
EP2789630A1 (en) * 2013-04-09 2014-10-15 EngMab AG Bispecific antibodies against CD3e and ROR1
SG10201913680PA (en) 2014-05-29 2020-03-30 Macrogenics Inc Tri-specific binding molecules that specifically bind to multiple cancer antigens and methods of use thereof
AU2015329966A1 (en) * 2014-10-09 2017-04-27 Engmab Sàrl Bispecific antibodies against CD3epsilon and ROR1 for use in the treatment of ovarian cancer
CA2963692A1 (en) 2014-10-09 2016-04-14 Engmab Ag Bispecific antibodies against cd3epsilon and ror1
JP6904902B2 (ja) 2014-12-05 2021-07-21 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ ドメイン交換抗体
WO2016094873A2 (en) 2014-12-12 2016-06-16 Emergent Product Development Seattle, Llc Receptor tyrosine kinase-like orphan receptor 1 binding proteins and related compositions and methods
AR103442A1 (es) 2015-01-16 2017-05-10 Juno Therapeutics Inc Anticuerpos y receptores de antígenos quiméricos específicos de ror1
WO2016142768A1 (en) * 2015-03-10 2016-09-15 Eureka Therapeutics, Inc. Ror2 antibody
WO2016187220A2 (en) 2015-05-18 2016-11-24 Five Prime Therapeutics, Inc. Anti-ror1 antibodies
KR102784293B1 (ko) 2015-09-21 2025-03-20 압테보 리서치 앤드 디벨롭먼트 엘엘씨 Cd3 결합 폴리펩타이드
CN109311982A (zh) * 2016-01-20 2019-02-05 斯克利普斯研究所 Ror2抗体组合物和相关方法
JP2019506158A (ja) 2016-01-22 2019-03-07 ヤンセン バイオテツク，インコーポレーテツド 抗ｒｏｒ１抗体、ｒｏｒ１×ｃｄ３二重特異性抗体、及びそれらの使用法
TW201730212A (zh) 2016-02-17 2017-09-01 宏觀基因股份有限公司 Ｒｏｒ１－結合分子及其使用方法
IL326918A (en) 2016-10-19 2026-05-01 Invenra Inc Antibody structures
WO2019148445A1 (en) 2018-02-02 2019-08-08 Adagene Inc. Precision/context-dependent activatable antibodies, and methods of making and using the same

Also Published As

Publication number Publication date
WO2019204564A9 (en) 2019-12-12
EA202092202A1 (ru) 2021-07-23
IL278061A (en) 2020-11-30
US20210155692A1 (en) 2021-05-27
WO2019204564A1 (en) 2019-10-24
JP2025137618A (ja) 2025-09-19
AU2026202585A1 (en) 2026-04-30
AU2019256431B2 (en) 2026-01-15
MX2025001900A (es) 2025-04-02
US12084496B2 (en) 2024-09-10
BR112020021269A2 (pt) 2021-03-16
MY207121A (en) 2025-01-31
JP2021522162A (ja) 2021-08-30
MX2025001906A (es) 2025-04-02
EP3797122A1 (en) 2021-03-31
MX2020010881A (es) 2020-11-09
KR20200143470A (ko) 2020-12-23
PH12020551716A1 (en) 2021-07-26
JP2023168551A (ja) 2023-11-24
SG11202010235QA (en) 2020-11-27
CA3097704A1 (en) 2019-10-24
US20240392002A1 (en) 2024-11-28
MX2025001902A (es) 2025-04-02
EP3797122A4 (en) 2022-04-20
AU2019256431A1 (en) 2020-11-05
CN112384533A (zh) 2021-02-19

Similar Documents

Publication Publication Date Title
US20240392002A1 (en) Anti-ror antibody constructs
JP7591015B2 (ja) 抗体構築物
US20250026861A1 (en) Trivalent trispecific antibody constructs
US20220213225A1 (en) Multispecific treg binding molecules
US20210163594A1 (en) Binding molecules
JP2024056787A (ja) 抗葉酸受容体１抗体及びその使用
US20220153844A1 (en) Multispecific treg binding molecules
EA048615B1 (ru) Конструкции антител к ror
WO2019183406A1 (en) Multispecific antibody purification with ch1 resin